Banner MD Anderson Cancer Center - University Medical Center Phoenix

Clinical research site in Phoenix, Arizona

As of July 2026, 2 paid clinical trials are recruiting at Banner MD Anderson Cancer Center - University Medical Center Phoenix in Phoenix, Arizona. Active studies at this site cover conditions such as Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma and Diffuse Large B-Cell Lymphoma. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at Banner MD Anderson Cancer Center - University Medical Center Phoenix (2)

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

for Chronic Lymphocytic Leukemia

43 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06136559·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

for Diffuse Large B-Cell Lymphoma

46 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06717347·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

Explore more

Paid clinical trials in Phoenix, AZ · Arizona clinical trials

Banner MD Anderson Cancer Center - University Medical Center Phoenix

Recruiting clinical trials at Banner MD Anderson Cancer Center - University Medical Center Phoenix (2)

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

More research sites in Phoenix

Explore more